Slingshot members are tracking this event:
FDA Designates Sangamo's (SGMO) SB-318 an Orphan Drug in Treatment of Mucopolysaccharidosis Type I (MPS I)
Slingshot Insights Explained
Jan 11, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Sb-318, Orphan Drug, Mucopolysaccharidosis Type I, Mps I, Fda